# Ferring Pharmaceuticals clinical trials: 249 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 249 trials with Ferring Pharmaceuticals as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ferring Pharmaceuticals: 249 rows for $12.45, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ferring-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 249
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 249, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 3, 2025 | NCT07152730 | A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump | Ferring Pharmaceuticals | Phase 1 | Withdrawn | Amenorrhea, Fertility, Infertility | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07152730) |
| June 19, 2025 | NCT07029451 | To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in... | Ferring Pharmaceuticals | Observational | Active not recruiting | Infertility | 2,549 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029451) |
| October 31, 2024 | NCT06668493 | Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis | Ferring Pharmaceuticals | Phase 1/2 | Recruiting | Low-grade Upper Tract Urothelial Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668493) |
| August 20, 2024 | NCT06561958 | Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women... | Ferring Pharmaceuticals | Observational | Active not recruiting | Infertility | 1,526 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06561958) |
| August 9, 2024 | NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With... | Ferring Pharmaceuticals | Phase 3 | Recruiting | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545955) |
| August 9, 2024 | NCT06545877 | REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies) | Ferring Pharmaceuticals | Observational | Completed | Infertility | 571 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545877) |
| July 23, 2024 | NCT06515834 | Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons | Ferring Pharmaceuticals | Phase 1 | Completed | Gastroenterology | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06515834) |
| July 22, 2024 | NCT06511791 | An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During... | Ferring Pharmaceuticals | Phase 1 | Terminated | Infertility | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06511791) |
| July 19, 2024 | NCT06510374 | Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Ferring Pharmaceuticals | Phase 3 | Recruiting | Intermediate Risk Non-Muscle Invasive Bladder Cancer | 454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06510374) |
| June 20, 2024 | NCT06466486 | An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation | Ferring Pharmaceuticals | Phase 1 | Terminated | Fertility | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06466486) |
| April 30, 2024 | NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response... | Ferring Pharmaceuticals | Phase 4 | Withdrawn | Bladder Cancer, Ta/T1, CIS | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06390111) |
| March 7, 2024 | NCT06298032 | A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons | Ferring Pharmaceuticals | Phase 1 | Completed | Inflammatory Gastrointestinal Diseases | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298032) |
| February 15, 2024 | NCT06260267 | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis | Ferring Pharmaceuticals | Phase 1 | Withdrawn | Ulcerative Colitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06260267) |
| December 18, 2023 | NCT06173869 | A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting... | Ferring Pharmaceuticals | Phase 3 | Completed | Infertility, Female | 301 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06173869) |
| September 7, 2023 | NCT06026332 | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting | Ferring Pharmaceuticals | Observational | Terminated | Bladder Cancer | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06026332) |
| June 29, 2023 | NCT05924321 | A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects | Ferring Pharmaceuticals | Phase 1 | Completed | Postpartum Hemorrhage | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05924321) |
| April 28, 2023 | NCT05835219 | REBYOTA™ Prospective Registry | Ferring Pharmaceuticals | Observational | Completed | Recurrence of Clostridium Difficile Infection | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05835219) |
| April 26, 2023 | NCT05831189 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With... | Ferring Pharmaceuticals | Phase 3 | Completed | Clostridium Difficile Infection Recurrence | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05831189) |
| January 30, 2023 | NCT05704244 | Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive... | Ferring Pharmaceuticals | Phase 3 | Active not recruiting | Bladder Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05704244) |
| October 7, 2022 | NCT05571111 | Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final... | Ferring Pharmaceuticals | Phase 2 | Withdrawn | Infertility | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05571111) |
| August 12, 2022 | NCT05499052 | Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection... | Ferring Pharmaceuticals | Observational | Completed | Controlled Ovarian Stimulation | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05499052) |
| June 3, 2022 | NCT05403476 | A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic... | Ferring Pharmaceuticals | Phase 2 | Terminated | Male Idiopathic Infertility | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05403476) |
| March 2, 2022 | NCT05263388 | A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation | Ferring Pharmaceuticals | Phase 3 | Completed | Infertility | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05263388) |
| January 6, 2022 | NCT05181800 | FIRMAGON® Intensive Drug Monitoring | Ferring Pharmaceuticals | Observational | Completed | Prostate Cancer | 1,454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05181800) |
| May 26, 2021 | NCT04902131 | A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women | Ferring Pharmaceuticals | Phase 1 | Completed | Infertility, Female | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04902131) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 4 |
| Phase 2 | 51 |
| Phase 2/3 | 6 |
| Phase 3 | 87 |
| Phase 4 | 15 |
| Not applicable | 3 |
| Observational | 70 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 207 |
| Terminated | 26 |
| Withdrawn | 9 |
| Recruiting | 4 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Prostatic Neoplasms | 41 |
| Infertility | 38 |
| Colitis, Ulcerative | 18 |
| Nocturia | 18 |
| Crohn Disease | 10 |
| Infertility, Female | 9 |
| Dwarfism, Pituitary | 5 |
| Menorrhagia | 5 |
| Eunuchism | 4 |
| Urinary Bladder Neoplasms | 3 |
| Nocturnal Enuresis | 3 |
| Shock, Septic | 3 |
| Turner Syndrome | 3 |
| Premature Birth | 2 |
| Osteoarthritis, Knee | 2 |
| Inflammatory Bowel Diseases | 2 |
| Osteoarthritis | 2 |
| Ovarian Hyperstimulation Syndrome | 2 |
| Non-Muscle Invasive Bladder Neoplasms | 2 |
| Anovulation | 2 |
| Constipation | 2 |
| Growth Disorders | 1 |
| Diarrhea | 1 |
| Enterocolitis, Pseudomembranous | 1 |
| Urinary Bladder, Overactive | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
